Sigfox France Demonstrates the 0G Potential in Response to the Scheduled Shutdown of the Public Switched Telephone Network (PSTN)
14.5.2019 14:35:00 EEST | Business Wire | Press release
Within three years, all switched networks will have disappeared and most of them will be replaced by exchanges based on the IP protocol, with or without wires. This standardization of exchanges allows substantial gains in telecommunications infrastructures, but it generates significant costs for migrating from existing solutions based on switched networks. A lot of equipment will have to be adapted or replaced without creating added value or new services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005512/en/
The MutaKom box (Photo: Sigfox)
In order to meet this major challenge, which will impact millions of devices, Sigfox, the world's leading IoT service provider and first global 0G network operator, and J2C, a specialist in service offerings in the security market, have developed the MutaKom box, which replaces the previous wiring that linked the devices to the PSTN. The MutaKom solution offers immediate service continuity and is economically unbeatable.
The PSTN still satisfies multiple uses including: telemetry, remote reading, remote monitoring of premises, remote maintenance or remote alarms of machines, gauges, industrial automatons and alarm centres. All these equipments amount to a fleet of several million units, in France only, which will quickly need to find a simple, immediate and inexpensive alternative link.
The market for alarm control units in France only is estimated at 1.2 million (GPMSE and ADMS sources). The stakes around the termination of the PSTN are therefore crucial. With MutaKom providing an optional backup battery, alarm centres will maintain a similar energy autonomy, while increasing security against hacking or sabotage attempts. Indeed, the wireless link provided by the Sigfox 0G network is resistant to all types of jammers, and makes it impossible to cut the telephone cable to isolate the alarm from the remote monitor.
As Patrick Cason, Managing Director at Sigfox France, points out: "We are targeting a large market in Europe with millions of alarm centres and other technical equipment for which the only solution, before the arrival of the MutaKom offer, was to migrate to more expensive equipment without real added value. With this in mind, MutaKom is, in our opinion, the most competitive offer on the market”.
Christophe Sautter, Executive President of the GIP Group (Générale Industrielle de Protection), first security player in France to test the MutaKom solution: "The first tests were more than convincing. We believe that the simplicity of implementation and cost savings will be significant with a tangible impact on customer satisfaction”.
This Sigfox network application illustrates once again the potential of the 0G network to permanently or temporarily compensate for the unavailability of existing networks. The 0G standard is there to provide a minimal and functional link to serve the successive changes in telecommunications networks, which tend to become more complex in order to deliver ever more speed, while usage remains simple.
More information on MutaKom offer: www.mutakom.fr
About Sigfox
Sigfox is the initiator of the 0G network and
the world’s leading IoT (Internet of Things) service provider. Its
global network allows billions of devices to connect to the Internet, in
a straightforward way, while consuming as little energy as possible.
Sigfox unique approach to device-to-cloud communications addresses the
three greatest barriers to global IoT adoption: cost, energy consumption
and global scalability.
Today, the network is available in 60 countries, with 1 billion people covered. ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox empowers companies to move their business model towards more digital services, in key areas such as Asset Tracking and Supply Chain. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in France, and also has offices in Madrid, Munich, Boston, Dallas, San Jose, Dubai, Singapore, Sao Paulo and Tokyo.
About J2C
J2C is a new French player, based in Montpellier,
created by specialists in the security and telecommunications market,
whose mission is to propose new service offers on the security market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005512/en/
Contact information
Press:
Sigfox
Antoine Mège, PR & Content Manager
antoine.mege@sigfox.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release
The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
